However, high Bcl-2 expression does not confer resistance towards Bcl-xl inhibition as shown in a study by Punnoose et al. in multiple myeloma pointing towards Bcl-xl as a more promising target in tumors expressing both Bcl-2 and Bcl-xl18. This evidence concerns the gene BCL2L1 and AL amyloidosis.